Cabiralizumab
(also known as FPA008) is a humanized IgG4 monoclonal antibody that binds to
human colony stimulating factor 1 receptor (CSF1R), and blocks the ability of
IL34 and CSF1 to activate CSF1R expressed on macrophages. Cabiralizumab
specifically targets macrophages and monocytes, immune cells that are activated
or elevated in multiple disease settings [1, 2].
Showing posts with label Cabiralizumab. Show all posts
Showing posts with label Cabiralizumab. Show all posts
Subscribe to:
Posts (Atom)